Jubilant Pharmova Limited (NSE: JUBLPHARMA) reported a Revenue from Operations of ₹1,533.22 Crores, a boost of 18% growth from the previous year. The Net Loss for the business is ₹16.04 Crore from the profit of ₹50.80 Crore year on year. Earnings per Share is -₹0.98 for this quarter.
Jubilant Pharmova Limited Q3 FY23; Revenue Increased By 18%
Tags: pharmaceuticals
Related Post
- Kellton Tech Solutions Limited posts double-digit Q3 FY26 growth as digital transformation drives revenue; margins improve
Kellton Tech Solutions Limited (NSE: KELLTONTEC, BSE: 519602) reported double-digit year-on-year growth in revenue and…
-
Inox Green Energy Services Limited approves Q3 FY26 results and reappoints whole-time director
Inox Green Energy Services Limited (NSE: INOXGREEN, BSE: 543667) said its board approved the unaudited…
-
Huhtamaki India Limited reports flat Q4 2025 sales as margins improve on favorable mix and efficiency gains
Huhtamaki India Limited (NSE: HUHTAMAKI, BSE: 509820) reported broadly flat revenue in the fourth quarter…